GoLYTELY
(Polyethylene Glycol 3350)ApprovedSmall molecule
BayerIt's used to treat constipation by drawing water into the bowels to soften stool and make it easier to pass. It's also used to cleanse the bowels before medical procedures like colonoscopies.[2] GoLYTELY is currently approved and in use across 10 indications[4].[1]
GoLYTELY is one of 152 small molecule programs targeting Constipation Disorder. It is currently in Approved.
10
Indications
20
Total Trials
4
Active Trials
151
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
107 competitors in Cystic Fibrosis
#DrugCompanyPhaseTrials
1GoLYTELY
BayerApproved
Ibsrela
AArdelyx
Phase 3
Zyvox
PfizerPhase 2
HSK31858
Haisco Pharmaceutical Group Co., Ltd.Phase 3
Sirturo
WWim Janssens
Phase 2
Amoxil
GGlobal Antibiotics Research and Development Partnership
Phase 2
ELX/TEZ/IVA
Vertex PharmaceuticalsPhase 3
Trimethoprim-Sulfamethoxazole
AstellasPhase 2
Trikafta
NNottingham University Hospitals NHS Trust
Phase 3
VNZ/TEZ/D-IVA
Vertex PharmaceuticalsPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Constipation5 trials
Crohn's Disease2 trials
Encephalopathy1 trial
10 more indications
Cystic Fibrosis1 trial
Bowel Preparation for Colonoscopy1 trial
Urologic Surgery1 trial
Preop Laxatives in Robotic Urologic Surgery
Recruiting·—·Phase 4·NCT05805436·240 enrolled
Urogynecologic Surgery1 trial
Regulatory
FDA Approval Timeline[5]
Oct 6, 2006
MIRALAX
NDA NDA022015
Sources
References
- [1]
- [2]MedlinePlus Drug Information — GoLYTELY drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Polyethylene Glycol 3350. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]